Drug Profile
Trilostane
Alternative Names: Abetafen; Modrastane; Modrefen; ModrenalLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Stegram Pharmaceuticals
- Class Androstanols; Testosterone congeners
- Mechanism of Action 3-hydroxysteroid dehydrogenase inhibitors; Estrogen receptor antagonists; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- No development reported Adrenal cortical hyperfunction; Prostate cancer
- Discontinued Alzheimer's disease
Most Recent Events
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 08 Sep 2009 No development reported - Clinical for Breast cancer in European Union (PO)
- 08 Sep 2009 No development reported - Clinical-Phase-Unknown for Breast cancer in Australia (PO)